Skip to main content
Manufacturing Facility)

Product Pipeline

Focused on Innovation

CSL Behring is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma fractionation, recombinant technology, and cell and gene therapy to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in five Therapeutic Areas - Immunology, Hematology, Cardiovascular and Metabolic, Respiratory and Transplant. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth.

Core Capabilities


Phase 1

Phase 2

Phase 3

Registration / Post-Registration

R&D Portfolio
Phase 3

Garadacimab Anti-FXIIa mAb (HAE)

Humanised anti-factor XIIa monoclonal antibody for the potential treatment of Hereditary Angioedema (HAE) by subcutaneous administration.

HIZENTRA® (DM)

20% subcutaneous immunoglobulin for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM).

EtranaDez Etranacogene dezaparvovec (Hem B)

Recombinant adeno-associated viral vector of serotype 5 (AAV5) gene therapy containing the Padua variant of a codon-optimized human FIX complementary deoxyribonucleic acid (AAV5-Padua hFIX) for the treatment of Hemophilia B.

KCENTRA® 4F-PCC (Trauma)

A 4-factor prothrombin complex concentrate (4F-PCC) for the potential treatment of massive hemorrhage associated with severe traumatic injury.

CSL112 ApoA-I (AMI)

Novel apolipoprotein A-I infusion therapy to potentially reduce the risk of major adverse cardiovascular events (MACE) in patients with myocardial infarction (AMI).

Clazakizumab Anti-IL-6 mAb (AMR)

Humanized recombinant monoclonal antibody targeting interleukin-6 (IL-6) for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients.

CSL964 Alpha-1 Antitrypsin (Prevention of GvHD)

Prevention of acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).

CSL964 Alpha-1 Antitrypsin (Treatment of GvHD)*

Treatment of steroid refractory, acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).
*In collaboration with Blood and Marrow Transplant Clinical Trials Network (BMT CTN)